Literature DB >> 2806325

Prolonged lung retention of 123I-IMP in pulmonary disease.

H Ikeda1, M Mariko, M Komatsu, K Takahashi, S Yasui, K Takahashi.   

Abstract

The accumulation of venously injected 123I-IMP in the lung was studied. Between 30 and 50 min after the injection of the 1.5 mCi 123I-IMP, the concentration of 123I-IMP in the broncho-alveolar lavage fluid were much higher than in the blood. It was considered that 123I-IMP was transported into the alveolar spaces and was absorbed by the alveolar cells. The half time (T1/2) of the 123I-IMP release from the lung between 10 and 25 min immediately after the injection was calculated. In normal subjects the T1/2 ranged between 25 and 44 min and was prolonged in subjects with pulmonary fibrosis, sarcoidosis, and allergic alveolitis. It was considered that the retention of 123I-IMP was related not only to the endothelial cells, but also to the alveolar cells. It was considered that the analysis of the lung release of 123I-IMP forms a new lung dysfunction index.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2806325     DOI: 10.1007/bf00251677

Source DB:  PubMed          Journal:  Eur J Nucl Med        ISSN: 0340-6997


  11 in total

1.  Metabolism, production, and release of hormones and mediators in the lung.

Authors:  A F Junod
Journal:  Am Rev Respir Dis       Date:  1975-07

2.  In vivo chemistry of iofetamine HCl iodine-123 (IMP).

Authors:  R M Baldwin; J L Wu
Journal:  J Nucl Med       Date:  1988-01       Impact factor: 10.057

3.  Metabolic activities of the lung: introduction.

Authors:  J R Vane
Journal:  Ciba Found Symp       Date:  1980

4.  Biodistribution and dosimetry of N-isopropyl-p-[123I]iodoamphetamine in the primate.

Authors:  B L Holman; R E Zimmerman; J R Schapiro; M L Kaplan; A G Jones; T C Hill
Journal:  J Nucl Med       Date:  1983-10       Impact factor: 10.057

5.  A noninvasive procedure for in vivo assay of a lung amine endothelial receptor.

Authors:  J J Touya; J Rahimian; D E Grubbs; H F Corbus; L R Bennett
Journal:  J Nucl Med       Date:  1985-11       Impact factor: 10.057

6.  Xenobiotic accumulation and metabolism by isolated perfused rabbit lungs.

Authors:  T C Orton; M W Anderson; R D Pickett; T E Eling; J R Fouts
Journal:  J Pharmacol Exp Ther       Date:  1973-09       Impact factor: 4.030

Review 7.  The fate of circulating amines within the pulmonary circulation.

Authors:  C N Gillis; B R Pitt
Journal:  Annu Rev Physiol       Date:  1982       Impact factor: 19.318

8.  Measurement of metabolic extraction of tracers in the lung using a multiple indicator dilution technique.

Authors:  J Rahimian; E C Glass; J J Touya; S F Akber; L S Graham; L R Bennett
Journal:  J Nucl Med       Date:  1984-01       Impact factor: 10.057

9.  N-isopropyl-p[123I]iodoamphetamine, a new agent for lung imaging studies.

Authors:  N Van Zandwijk; A Zwijnenburg; C A Hoefnagel; H R Marcuse
Journal:  Thorax       Date:  1986-10       Impact factor: 9.139

10.  N-isopropyl-[123I] p-iodoamphetamine: single-pass brain uptake and washout; binding to brain synaptosomes; and localization in dog and monkey brain.

Authors:  H S Winchell; W D Horst; L Braun; W H Oldendorf; R Hattner; H Parker
Journal:  J Nucl Med       Date:  1980-10       Impact factor: 10.057

View more
  4 in total

1.  Prolonged lung retention of 123I-IMP in pulmonary fibrosis.

Authors:  H Ikeda; M Itasaka; K Takahashi; A Komatani
Journal:  Ann Nucl Med       Date:  1992-08       Impact factor: 2.668

2.  New design of N-isopropyl-p-[123I]iodoamphetamine (123I-IMP) lung imaging in the patient with lung cancer.

Authors:  E Tanaka; M Mishima; K Kawakami; N Sakai; N Sugiura; T Taniguchi; M Ohi; H Itoh; K Kuno
Journal:  Ann Nucl Med       Date:  1995-11       Impact factor: 2.668

3.  On clinical usefulness of Tl-201 scintigraphy for the management of malignant soft tissue tumors.

Authors:  S Terui; T Terauchi; H Abe; H Fukuma; Y Beppu; K Chuman; R Yokoyama
Journal:  Ann Nucl Med       Date:  1994-02       Impact factor: 2.668

4.  I-123 IMP scintigraphy in two patients with primary pulmonary malignant lymphoma.

Authors:  K Suga; K Nishigauchi; M Sadanaga; N Kume; H Uchisako; T Matsumoto; T Nakanishi
Journal:  Ann Nucl Med       Date:  1994-02       Impact factor: 2.668

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.